Valo Therapeutics is an immunooncology company developing tumour antigen-coated oncolytic viruses as therapeutic vaccines.
Valo Therapeutics has raised €33M across 4 funding rounds from 7 investors, most recently a round in Mar 2025. Based in Helsinki, Finland; founded 2016; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-03-10 | Other | €19M | CDP Venture Capital Sgr,ENEA Tech e Biomedical,Freeman Road,Indaco Venture Partners SGR | View deal → |
| 2023-02-15 | Other | €2.2M | European Innovation Council | View deal → |
| 2021-11-15 | Pre-Seed | €11M | Freeman Road,MMJ Group Holdings | View deal → |
| 2020-02-06 | Other | €1.1M | Business Finland | View deal → |
